Aarti Drugs
390.60
+7.05(+1.84%)
Market Cap₹3,565.01 Cr
PE Ratio17.59
IndustryHealthcare
Company Performance:
1D+1.84%
1M-4.95%
6M-20.20%
1Y-7.75%
5Y-42.39%
View Company Insightsright
More news about Aarti Drugs
25Jul 25
Aarti Drugs Reports 6% Revenue Growth in Q1, Margins Improve Amid Input Cost Normalization
Aarti Drugs Limited reported a 6% year-on-year revenue growth to INR591.00 crores for the first quarter, with a 5% growth in API business volumes. EBITDA increased by 12% to INR74.00 crores, and net profit rose to INR54.00 crores from INR33.30 crores in the previous year's Q1. The company's gross profit margin improved by 130 basis points to 36.80%. Aarti Drugs has commenced trial production for anti-diabetic products at its Sayakha, Gujarat facility and expects its Tarapur salicylic acid facility to contribute from Q3. The formulation business grew by 14% to INR80.00 crores. The company received USFDA and UK MHRA approvals for its facilities and has positioned itself as a leading global metformin manufacturer.
 no imag found
19Jul 25
Aarti Drugs Reports Strong Q1 FY26 Results, Expands Operations with New Facilities
Aarti Drugs Limited reported robust Q1 FY26 results with revenue up 6% YoY to Rs. 590.80 crores, EBITDA up 12% YoY to Rs. 74.40 crores, and PAT up 62% YoY to Rs. 54.00 crores. The company is expanding operations with a new Salicylic Acid plant in Tarapur and a greenfield facility in Sayakha, Gujarat. Aarti Drugs is positioned to benefit from potential U.S. market opportunities due to high tariffs on Chinese imports. The company's formulation subsidiary received USFDA and UKMHRA approvals for its facilities.
 no imag found
19Jul 25
Aarti Drugs Reports 6% Revenue Growth in Q1 FY26, Allocates Rs. 48.5 Crore for Capex
Aarti Drugs Limited reported a 6% year-on-year increase in revenue to Rs. 590.80 crore for Q1 FY26. The company saw improved profitability with EBITDA growing 12% to Rs. 74.40 crore and PAT surging 62% to Rs. 54.00 crore. All business segments showed growth, with API segment revenue at Rs. 458.20 crore. The company spent Rs. 48.50 crore on capex during Q1 and projects total FY26 capex between Rs. 150-200 crore. Expansion plans include a new facility in Gujarat and a Salicylic Acid plant in Tarapur.
 no imag found
18Jul 25
Aarti Drugs: Q1 Profit Surges 63%, Margins Improve
Aarti Drugs Limited announced strong Q1 financial results with net profit soaring 62.70% year-on-year to ₹54.00 crore. Revenue increased by 6.30% to ₹590.00 crore, while EBITDA grew 13.85% to ₹74.00 crore. The company's EBITDA margin improved to 12.60% from 11.70% year-over-year, indicating enhanced operational efficiency.
 no imag found
07May 25
Aarti Drugs Reports Robust Q4 Performance with Significant Profit and Revenue Growth
Aarti Drugs Limited announced impressive Q4 financial results with consolidated net profit reaching ₹628.60 crore, up 32.61% year-over-year. Revenue increased to ₹677.00 crore, a 9.19% rise from the previous year. The company also saw a significant quarter-over-quarter profit growth of 69.66%.
 no imag found
06May 25
Aarti Drugs Unveils Ambitious Production Expansion Strategy Through FY26
Aarti Drugs Limited has announced a strategic plan to significantly increase its production capacity. The company aims to boost production to over 700 tonnes per month by June 2025 and reach approximately 1,600 tonnes per month by the end of fiscal year 2026. This expansion is expected to enhance the company's market position and ability to meet growing demand in the pharmaceutical sector.
 no imag found
06May 25
Aarti Drugs Reports Strong Q4 FY2023 Results: Profit Surges 33%, Revenue Up 9%
Aarti Drugs Limited announced impressive Q4 FY2023 financial results. Net profit rose 32.7% YoY to ₹62.86 crore, while revenue increased 9.2% to ₹677.00 crore. EBITDA grew 8.9% to ₹93.40 crore, with a stable EBITDA margin of 13.79%. The company showed significant quarter-on-quarter growth, with net profit jumping 69.7% from Q3 FY2023. These results highlight Aarti Drugs' strong market position, operational efficiency, and growth potential in the pharmaceutical sector.
 no imag found
07Mar 25
SEBI Issues Administrative Warning to Aarti Drugs for Insider Trading Regulation Violations
Aarti Drugs Limited has received an administrative warning letter from SEBI for alleged violations of insider trading regulations. The warning cites inadequate identification of immediate relatives of designated persons and non-application of the Code of Conduct on Prohibition of Insider Trading to certain immediate relatives. The company has committed to ensuring compliance and exercising caution to prevent recurrence. No financial impact or penalties have been imposed on the company.
 no imag found
06Mar 25
SEBI Issues Administrative Warning to Aarti Drugs' Compliance Officer Amid Insider Trading Concerns
SEBI has issued an administrative warning to Aarti Drugs Limited's Compliance Officer and Company Secretary for potential violations of insider trading regulations. The warning cites inadequate steps in identifying immediate relatives of Designated Persons and failure to apply the Code of Conduct on Prohibition of Insider Trading to certain relatives. Aarti Drugs has committed to ensuring compliance and exercising caution to prevent recurrence. The company states that this warning will not impact its financial, operational, or other activities.
 no imag found
Aarti Drugs
390.60
+7.05
(+1.84%)
1 Year Returns:-7.75%
Industry Peers
Sun Pharmaceutical
1,702.10
(+4.56%)
Divis Laboratories
6,209.00
(+4.31%)
Torrent Pharmaceuticals
4,045.60
(+1.46%)
Cipla
1,322.80
(+0.85%)
Dr Reddys Laboratories
1,235.40
(+4.47%)
Lupin
2,185.90
(+2.65%)
Zydus Life Science
902.90
(+2.64%)
Mankind Pharma
2,162.60
(+4.79%)
Aurobindo Pharma
1,226.10
(+4.71%)
Alkem Laboratories
5,702.50
(+3.28%)